

- Hypomagnesemia (Cont.):**  
 genetic considerations in, 2461–2462  
 hypocalcemia and, 2484  
 hypokalemia and, 64e-8, 305, 306–307  
 hypoparathyroidism and, 2484  
 inpatient neurologic consultation for, 463e-4  
 with parenteral nutrition, 98e-7t  
 primary, 332e-7t  
 treatment of, 64e-8–9, 307, 2462, 2484  
 vitamin D deficiency and, 2462
- Hypomelanosis, 357, 357t, 358t**  
**Hypomelanosis of Ito (linear nevoid hypopigmentation), 357, 357t**
- Hypometabolic states, 460**  
 anemia in, 630–631, 630t  
 gluconeogenesis in, 461  
 metabolic rate in, 461  
 physiologic characteristics of, 460–461, 460t  
 protein catabolism in, 461
- Hyponatremia, 298, 2280**  
 in acute kidney injury, 1808  
 in adrenal insufficiency, 2324  
 after subarachnoid hemorrhage, 300, 1785–1786  
 chronic, 64e-5–6, 301, 303  
 in chronic kidney disease, 1814  
 clinical features of, 300–301, 2280  
 diagnosis of, 299f, 301  
 differential diagnosis of, 2281, 2282t  
 etiology of, 301t, 332e-10f, 2280–2281  
 euvoletic, 299–300, 2280, 2282t. *See also* Syndrome of inappropriate antidiuretic hormone (SIADH)  
 exercise-associated, 300–301  
 global considerations in, 2283  
 hypervolemic  
 differential diagnosis of, 2282t  
 disorders associated with, 299, 2280  
 pathophysiology of, 299, 2281  
 treatment of, 302, 2282–2283  
 hypokalemia and, 302  
 hypovolemic  
 differential diagnosis of, 301, 2282t  
 disorders associated with, 299, 2280  
 pathophysiology of, 298–299, 2281  
 treatment of, 64e-5–6, 302  
 inpatient neurologic consultation for, 463e-3–4  
 with low solute intake, 300  
 in lung cancer, 511  
 paraneoplastic, 610  
 with parenteral nutrition, 98e-7t  
 pathophysiology of, 2281  
 treatment of, 64e-5–6, 302–303, 463e-3–4, 2281–2283
- Hypoparathyroidism**  
 acquired, 2483–2484  
 APS-1 and, 2345, 2346t  
 APS-2 and, 2347t  
 chronic, 2483–2484  
 clinical features of, 2482–2483  
 etiology of, 314t, 2482t  
 genetic syndromes associated with, 2483  
 hyperphosphatemia due to, 2460  
 hypocalcemia and, 314–315, 314t, 2482–2483  
 muscle involvement in, 462e-19  
 transient, 2484  
 treatment of, 2484
- Hypoparathyroidism, deafness, and renal dysplasia (HDR) syndrome, 2483**
- Hypophosphatasia, 237, 426e-1, 426e-5–6**  
**Hypophosphatemia, 2458**  
 clinical features of, 96e-9t, 463t, 1563, 2459–2460  
 etiology of, 2458–2459, 2459t  
 in hospitalized patients, 461  
 hypokalemia and, 64e-7  
 in oncogenic osteomalacia, 612  
 osteomalacia and, 2465. *See also* Osteomalacia with parenteral nutrition, 98e-7t  
 treatment of, 2460, 2460t
- Hypophysectomy, for breast cancer, 530t**  
**Hypophysitis, 2257, 2346t, 2347t**
- Hypopigmentation, 357**  
 diffuse, 357  
 etiology of, 357, 357t, 358t, 359  
 linear nevoid, 357, 357t  
 localized, 357  
 postinflammatory, 358t, 359
- Hypopituitarism, 2255**  
 acquired causes of, 2256–2257  
 clinical features of, 2257  
 developmental and genetic causes of, 2256–2257  
 etiology of, 2255–2257, 2255t  
 hypothermia in, 478e-1  
 laboratory investigation of, 2257, 2258t  
 oral manifestations of, 236  
 treatment of, 2257, 2259t
- Hypoproliferative anemia, 398, 625, 630, 631, 662. See also** Aplastic anemia; Iron-deficiency anemia
- Hypoproteinemia, 253**  
**Hyposensitization. See** Immunotherapy
- Hyposmia. See** Olfactory disorders
- Hypospadias, isolated, 2355**  
**Hyposplenism, 413. See also** Splenectomy
- Hypotension**  
 in coma, 1773  
 in gastrointestinal bleeding, 277  
 in heatstroke, 479e-4  
 in hemodialysis, 1824  
 in hypovolemia, 298  
 intracranial, 2607  
 in malabsorption syndromes, 1946t  
 in mechanically ventilated patient, 1743  
 orthostatic. *See* Orthostatic hypotension  
 in sepsis/septic shock, 1755  
 in shock, 1729–1730, 1731f, 1732f, 1744–1745  
 transfusion-related, 138e-5–6
- Hypothalamic amenorrhea, 336**
- Hypothalamic disease**  
 body temperature in, 124  
 hypopituitarism due to, 2256. *See also* Hypopituitarism
- Hypopituitarism**  
 IgG4-related, 391e-1t  
 metabolic effects of, 2264  
 obesity in, 415e-4  
 sellar masses, 2264–2265
- Hypothalamic gliomas, 2264**  
**Hypothalamic hamartomas, 2264**
- Hypothalamic-pituitary-adrenal (HPA) axis, 2310, 2310f**
- Hypothalamic-pituitary-gonadal axis, 335, 336f**  
**Hypothalamic-pituitary-testis axis, 2358, 2358f**  
**Hypothalamic-pituitary vasculature, 401e-2f**
- Hypothalamus**  
 age-related changes in, 76  
 developmental dysfunction of, 2256  
 in ovarian function regulation, 2376–2377, 2377f  
 in sleep onset, 185–186
- Hypothermia, 478e-1**  
 bradyarrhythmia in, 1467  
 clinical features of, 478e-1–2, 478e-2t  
 coma and, 1773  
 diagnosis of, 478e-2  
 drug-induced, 478e-1, 478e-1t  
 ECG in, 1457, 1458f  
 in elderly, 478e-1, 478e-1t, 478e-3  
 etiology of, 478e-1  
 in myxedema coma, 2293  
 physiologic changes in, 478e-2t  
 primary accidental, 478e-1  
 risk factors for, 478e-1t  
 SA node dysfunction in, 1467t  
 secondary, 478e-1  
 in shock, 1751  
 therapeutic, after cardiac resuscitation, 1770, 1781  
 treatment of, 478e-3, 1751
- Hypothyroidism, 2289**  
 autoimmune  
 classification of, 2290  
 clinical features of, 2290t, 2291, 2291f  
 differential diagnosis of, 2291  
 laboratory evaluation of, 2291
- pathogenesis of, 372e-24t, 377e-4–5, 2290–2291  
 prevalence of, 2290  
 clinical, 2290, 2292  
 clinical features of, 152, 2290t, 2291, 2291f  
 alopecia, 355  
 anemia, 630  
 ascites, 287  
 bleeding, 404  
 cardiac, 290e-1t, 290e-2  
 AV conduction block, 1471t  
 heart failure, 1563  
 SA node dysfunction, 1467, 1467t  
 carotenemia, 96e-7  
 cutaneous, 363  
 depression, 2714  
 edema, 253  
 hirsutism, 332  
 hypertension, 1620  
 hyponatremia, 299, 301  
 hypothermia, 478e-1, 478e-3  
 lipoprotein disorders, 2441  
 muscle involvement, 462e-18  
 neuropathy, 2683  
 obesity, 415e-4  
 congenital, 2283, 2284t, 2289–2290  
 diagnosis of, 2291, 2292f  
 differential diagnosis of, 2291  
 diseases associated with, 2291  
 etiology of, 2289t, 2292  
 in HIV infection, 1259–1260  
 iatrogenic, 2292  
 overt, 2290  
 pathogenesis of, 2290–2291  
 in pregnancy, 48, 49, 2293, 2300  
 prevalence of, 2254t, 2290  
 radiation therapy-related, 506, 623  
 screening/testing for, 2254t  
 secondary, 2292  
 subclinical, 2290, 2292–2293  
 treatment of, 2292–2293
- Hypotonic saline, 304. See also** Saline
- Hypouricemia, 332e-7t, 431e-3t, 431e-5, 435e-1t**  
**Hypoventilation. See also** Obstructive sleep apnea  
 central hypoventilation syndrome, 1722, 1782  
 clinical features of, 1720–1721, 1721t  
 diagnosis of, 1721–1722  
 hypoxia in, 247–248  
 in obesity, 415e-6, 1722  
 pathophysiology of, 1721f  
 respiratory acidosis in, 322  
 treatment of, 1722
- Hypovolemia, 297**  
 in acute blood loss, 393  
 in acute kidney injury, 1808  
 AVP levels and, 295, 296f  
 clinical features of, 298  
 diagnosis of, 298  
 endogenous response to, 1745  
 etiology of, 297–298  
 in myocardial infarction, 1607  
 treatment of, 298
- Hypovolemic shock, 1748**  
 clinical features of, 21t, 298, 393, 1748  
 diagnosis of, 1748  
 hemodynamic patterns in, 1762t  
 initial assessment of, 1729  
 physiologic characteristics of, 1748t  
 predictors of fluid responsiveness in, 1729, 1731f, 1732f  
 treatment of, 1749–1750
- Hypoxanthine phosphoribosyltransferase (HPRT), 431e-2**  
**Hypoxanthine phosphoribosyltransferase (HPRT) deficiency, 431e-3t, 431e-5**
- Hypoxemia, 47e-5, 392, 1755**
- Hypoxia, 247**  
 in acute kidney injury, 333e-5  
 adaptation to, 248  
 in angiogenesis, 102e-14, 102e-16f  
 effects of, 247  
 etiology of, 247–248  
 SA node dysfunction in, 1467, 1467t